Literature DB >> 3570627

Control of epidemic group A meningococcal meningitis in Nepal.

S L Cochi, L E Markowitz, D D Joshi, R C Owens, D H Stenhouse, D N Regmi, R P Shrestha, I Lacharya, M Manandhar, V L Gurubacharya.   

Abstract

During the first six months of 1983, an epidemic of serogroup A meningococcal meningitis occurred in the Kathmandu valley of Nepal, resulting in 875 cases and 95 deaths. The annual attack rate was 103 cases per 100,000 population, with a peak attack rate occurring in April. Epidemic meningococcal disease had not been recognized previously in Nepal. Early in 1984, a review of hospital-based data on pyogenic meningitis in Kathmandu showed three times as many cases per month compared with the same period the previous year, suggesting that a recurrent epidemic was unfolding. Beginning in February 1984, a vaccination campaign directed at a high-risk target population of people aged 1-24 years was launched; over 329,000 doses of bivalent A/C meningococcal vaccine were given, achieving approximately 64% coverage of the target population. A dramatic decline in the number of new meningitis cases occurred coincident with the initiation of the mass vaccination campaign. This experience demonstrates that it is possible, with appropriate surveillance efforts, to detect an evolving epidemic of meningococcal disease early in its course and to institute control measures in advance of the expected epidemic peak.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570627     DOI: 10.1093/ije/16.1.91

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  9 in total

1.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

2.  Control of meningococcal epidemics.

Authors:  H Peltola
Journal:  Indian J Pediatr       Date:  1987 Mar-Apr       Impact factor: 1.967

Review 3.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

5.  Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992.

Authors:  Y M al-Gahtani; H E el Bushra; S M al-Qarawi; A A al-Zubaidi; R E Fontaine
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

6.  Characterization of epidemic and nonepidemic Neisseria meningitidis serogroup A strains from Sudan and Sweden.

Authors:  M A Salih; D Danielsson; A Bäckman; D A Caugant; M Achtman; P Olcén
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

7.  Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses.

Authors:  David S Berry; Freyja Lynn; Che-Hung Lee; Carl E Frasch; Margaret C Bash
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

Review 8.  Meningococcal disease in Asia: an under-recognized public health burden.

Authors:  A Vyse; J M Wolter; J Chen; T Ng; M Soriano-Gabarro
Journal:  Epidemiol Infect       Date:  2011-04-15       Impact factor: 2.451

9.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.